Abstract
There is increasing evidence that acute bacterial and viral infection represent trigger factors that temporarily elevate the risk of ischemic stroke. During and after influenza epidemics vascular death rates and hospitalizations for stroke are increased. Influenza vaccination is an effective measure to reduce hospitalization and mortality in the elderly and work incapacity in adults of working age. Results of several observational studies support the hypothesis that influenza vaccination is associated with reduced odds of stroke. As randomized studies are lacking, a causal role of influenza vaccination in stroke prevention is not proven, however. According to current guidelines in many countries, that recommend the vaccination in all patients with chronic vascular disease, all patients with a history of stroke or TIA should receive an influenza vaccination annually. Furthermore, patients with diabetes mellitus or with a combination of risk factors that increase stroke risk should obtain the vaccination. In addition, there is evidence from observational data that the neuraminidase inhibitor oseltamivir reduces the risk of stroke within 6 months after influenza infection.
Keywords: Acute infections, influenza, stroke, risk factor, cerebral ischemia, vascular disease, vaccination, antivirals
Infectious Disorders - Drug Targets
Title: Influenza and Stroke Risk: A Key Target Not to be Missed?
Volume: 10 Issue: 2
Author(s): Christian Urbanek, Frederick Palm and Armin J. Grau
Affiliation:
Keywords: Acute infections, influenza, stroke, risk factor, cerebral ischemia, vascular disease, vaccination, antivirals
Abstract: There is increasing evidence that acute bacterial and viral infection represent trigger factors that temporarily elevate the risk of ischemic stroke. During and after influenza epidemics vascular death rates and hospitalizations for stroke are increased. Influenza vaccination is an effective measure to reduce hospitalization and mortality in the elderly and work incapacity in adults of working age. Results of several observational studies support the hypothesis that influenza vaccination is associated with reduced odds of stroke. As randomized studies are lacking, a causal role of influenza vaccination in stroke prevention is not proven, however. According to current guidelines in many countries, that recommend the vaccination in all patients with chronic vascular disease, all patients with a history of stroke or TIA should receive an influenza vaccination annually. Furthermore, patients with diabetes mellitus or with a combination of risk factors that increase stroke risk should obtain the vaccination. In addition, there is evidence from observational data that the neuraminidase inhibitor oseltamivir reduces the risk of stroke within 6 months after influenza infection.
Export Options
About this article
Cite this article as:
Urbanek Christian, Palm Frederick and Grau J. Armin, Influenza and Stroke Risk: A Key Target Not to be Missed?, Infectious Disorders - Drug Targets 2010; 10 (2) . https://dx.doi.org/10.2174/187152610790963474
DOI https://dx.doi.org/10.2174/187152610790963474 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Obesity and Inflammation and Altered Clopidogrel Pharmacokinetics and Pharmacodynamics
Drug Metabolism Letters Calcium Store Stability as an Antiarrhythmic Endpoint
Current Pharmaceutical Design Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Drugs and Foods for Chronic Subclinical Inflammation in Humans
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Bioenergetics and Mitochondrial Dysfunction in Aging: Recent Insights for a Therapeutical Approach
Current Pharmaceutical Design Nutri-epigenomic Studies Related to Neural Tube Defects: Does Folate Affect Neural Tube Closure Via Changes in DNA Methylation?
Mini-Reviews in Medicinal Chemistry The New Adipose Tissue and Adipocytokines
Current Diabetes Reviews Matrix Metalloproteinases as Valid Clinical Target
Current Pharmaceutical Design Overview of Current Trends and the Future of Thromboprophylaxis in Orthopaedic Surgery
Vascular Disease Prevention (Discontinued) Cholesterol, Copper and Aβ in Controls, MCI, AD and the AD Cholesterol- Lowering Treatment Trial (ADCLT)
Current Alzheimer Research ApoA-I Mimetic Peptides as Anti-Inflammatory Agents
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Intradialytic Hypertension: An Under-recognized Cardiovascular Risk Factor. What is the Evidence?
Current Hypertension Reviews 5-HT7 Receptors
Current Drug Targets - CNS & Neurological Disorders Uric Acid and Hypertension
Current Pharmaceutical Design Leptin: A Promising Therapeutic Target with Pleiotropic Action Besides Body Weight Regulation
Current Drug Targets Smooth Muscle Cell Pathophysiology and Advanced Glycation End Products (AGEs)
Current Drug Targets Polydeoxyribonucleotide (PDRN): A Safe Approach to Induce Therapeutic Angiogenesis in Peripheral Artery Occlusive Disease and in Diabetic Foot Ulcers
Cardiovascular & Hematological Agents in Medicinal Chemistry Nutraceuticals and their Novel Drug Delivery System: A Boon to Human Health
Current Nutrition & Food Science Structural Neuroimaging Findings in Major Depressive Disorder Throughout Aging: A Critical Systematic Review of Prospective Studies
CNS & Neurological Disorders - Drug Targets